Patent 11746158 was granted and assigned to Crescendo Biologics on September, 2023 by the United States Patent and Trademark Office.
The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.